<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="995">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919162</url>
  </required_header>
  <id_info>
    <org_study_id>PBD-01187</org_study_id>
    <secondary_id>1R01AG061146-01</secondary_id>
    <nct_id>NCT03919162</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD</brief_title>
  <acronym>VIVA-MIND</acronym>
  <official_title>A Phase 2A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Varoglutamstat (PQ912) in Patients With Early Alzheimer's Disease With a Stage-Gate to Phase 2B (VIVA-MIND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivoryon Therapeutics N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Disease Cooperative Study (ADCS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vivoryon Therapeutics N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2A multi-center, randomized, double blind, placebo-controlled, parallel group&#xD;
      study of varoglutamstat, with a stage gate to phase 2B.&#xD;
&#xD;
      In phase 2A there will be adaptive dosing evaluation of three dose levels with exposure to&#xD;
      varoglutamstat or placebo for a minimum of 24 weeks, with preliminary evaluation of both&#xD;
      cognitive function and pharmacodynamic changes on EEG spectral analysis in approximately 180&#xD;
      participants.&#xD;
&#xD;
      In the event that the stage gate for phase 2B is reached, then phase 2B will assesses&#xD;
      efficacy and longer-term safety in a larger study group, i.e., 414.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to advance a first-in-class, new small molecule treatment for early&#xD;
      Alzheimer's disease (AD). Varoglutamstat (PQ912) is an oral, twice daily medication that&#xD;
      addresses a novel and significantly differentiated amyloid target: N-terminal&#xD;
      post-translationally modified Ab (pGlu-Ab), a particularly toxic subspecies of amyloid beta&#xD;
      (Ab). This study will further evaluate whether varoglutamstat's mechanism of action can&#xD;
      result in a measurable therapeutic effect on cognition, function and relevant pharmacodynamic&#xD;
      and biological markers in early AD.&#xD;
&#xD;
      The study is a phase 2A multi-center, randomized, double-blind, parallel group trial, with a&#xD;
      stage gate to phase 2B. Phase 2A will determine the highest dose that is both safe and well&#xD;
      tolerated. During this phase, there is an adaptive dosing evaluation, using a well-defined&#xD;
      safety stopping boundary, of three dose levels with exposure to varoglutamstat or placebo for&#xD;
      a minimum of 24 weeks to help determine which dose will be carried forward in phase 2B. A&#xD;
      sequential dose design will be employed in phase 2A where each of three dose cohorts are&#xD;
      randomized equally to placebo or varoglutamstat and treated for at least 8 weeks at the&#xD;
      originally assigned full dose. Participants will be randomized 1:1 to varoglutamstat or&#xD;
      placebo, and stratified between mild AD and MCI, as well as by site.&#xD;
&#xD;
      Phase 2A also includes preliminary evaluation of both cognitive function and pharmacodynamics&#xD;
      changes on electroencephalogram (EEG) spectral analysis.&#xD;
&#xD;
      In the event that the stage gate for phase 2B is reached from data in this phase 2A study,&#xD;
      then phase 2B will assess the longer-term efficacy and safety of varoglutamstat in a larger&#xD;
      study group, using the highest dose selected in phase 2A. In phase 2B, a composite cognitive&#xD;
      and functional measure as well as PD biomarkers will be used to evaluate efficacy during the&#xD;
      extended treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2A Primary safety: proportion of participants who experience any adverse event of interest (AE-I).</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary endpoint in phase 2A is the proportion of participants, for each dose, who experience any adverse event of interest (AE-I) during the safety reporting period, from first dose to completion of 8 weeks at the full originally assigned dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2A Primary PK: derived mean values of varoglutamstat levels and corresponding calculated target occupancy (TO)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The pharmacokinetics (PK) endpoints in Phase 2A are the derived mean values of varoglutamstat levels in plasma and the correspondingcalculated TO in CSF, for each dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2A Primary efficacy: The within-participant change from baseline to week 24 in the composite sum of standardized scores from the ADNI Battery Composite (ABC, 9-item) compared between active arm and placebo.</measure>
    <time_frame>24 weeks</time_frame>
    <description>The ABC is a set of ADNI neuropsychological test measures, including: Category Fluency (Animals and Vegetables), Trail Making A and B, Digit Symbol Substitution, Boston Naming Test, Rey's Auditory and Verbal Learning Test (RAVLT, Immediate and Delayed), Digit Span Forward and Backward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2A Primary efficacy:The within-participant change from baseline to week 24 in quantitative EEG (global relative theta wave power)</measure>
    <time_frame>24 weeks</time_frame>
    <description>The within-participant change frombaseline to week 24 of the global relative theta wave power (4-8 Hz) compared between active arm and placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2B Primary efficacy: The within-participant change from baseline to week 72 in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score, compared between active arm and placebo.</measure>
    <time_frame>72 weeks</time_frame>
    <description>The CDR-SB evaluates cognition and everyday functioning incorporating both informant input and direct assessment of performance. It is scored on a five-point scale a five point scale with following five possible scores: 0 = Normal 0.5 = Very Mild Dementia&#xD;
= Mild Dementia&#xD;
= Moderate Dementia&#xD;
= Severe Dementia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary efficacy: CFC2, a cognitive-functional composite</measure>
    <time_frame>72 weeks</time_frame>
    <description>The key secondary objective in phase 2B is to evaluate the efficacy of PQ912 as measured by CFC2, a cognitive-functional composite, over a 72-week treatment period.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">414</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 4 weeks 150 mg BID, week 5-8 300 mg BID, week 9-24 600 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First 4 weeks 150 mg BID, week 5-24 300 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 weeks on 150 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PQ912</intervention_name>
    <description>PQ912 150 mg tablets</description>
    <arm_group_label>150 mg</arm_group_label>
    <arm_group_label>300 mg</arm_group_label>
    <arm_group_label>600 mg</arm_group_label>
    <other_name>Varoglutamstat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets to mimic PQ912 150 mg tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-89 (inclusive) at screening&#xD;
&#xD;
          -  Diagnosed as having Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD) or&#xD;
             Mild probable AD according to workgroups of the Diagnostic Guidelines of the National&#xD;
             Institute on Aging and Alzheimer's Association (NIA-AA)&#xD;
&#xD;
          -  Mini-Mental State Examination (MMSE) score 20-30 inclusive at screening&#xD;
&#xD;
          -  Montreal Cognitive Assessment score (MoCA) &lt; 26 at screening&#xD;
&#xD;
          -  Clinical Dementia Rating global score 0.5 or 1 with memory score of &gt; 0.5 at screening&#xD;
&#xD;
          -  Positive CSF AD biomarker signature&#xD;
&#xD;
          -  A brain MRI scan within 6 months of screening consistent with a diagnosis of&#xD;
             Alzheimer's disease&#xD;
&#xD;
          -  Participants must have a study partner who has frequent interaction with them&#xD;
             (approximately &gt;3-4 times per week), will be present for all clinic visits, and can&#xD;
             assist in compliance with study procedures.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ Significant neurodegenerative diseases and causes of dementia, other than AD,&#xD;
             including Parkinson's disease and Huntington's disease, vascular dementia, CJD&#xD;
             (Creutzfeldt-Jakob disease), LBD (Lewy Body dementia), PSP (Progressive Supranuclear&#xD;
             Palsy), AIDS (Acquired Immunodeficiency Syndrome), or NPH (normal pressure&#xD;
             hydrocephalus)&#xD;
&#xD;
          -  Meeting Diagnostic Criteria for Possible AD according to workgroups of the Diagnostic&#xD;
             Guidelines of the NIA-AA&#xD;
&#xD;
          -  Hepatic impairment defined as Child-Pugh class A or more severe liver impairment&#xD;
&#xD;
          -  History of moderate or severe skin reactions to medications or current moderate or&#xD;
             severe disease of the skin and subcutaneous tissues&#xD;
&#xD;
          -  History of a major depressive episode within the past 6 months of screening&#xD;
&#xD;
          -  History of diagnosis of schizophrenia&#xD;
&#xD;
          -  History of uncontrolled bipolar disorder within past five years of screening&#xD;
&#xD;
          -  History of seizures within past two years of screening&#xD;
&#xD;
          -  Contraindication to lumbar puncture and MRI&#xD;
&#xD;
          -  Participation in another clinical trial for an investigational agent and having taken&#xD;
             at least one dose of study drug, unless confirmed as having been on placebo, within 90&#xD;
             days prior to the baseline visit. The end of a previous investigational trial is&#xD;
             defined as the date of the last dose of an investigational agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Feldman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alzheimer's Disease Cooperative Study (ADCS)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Archana Balasubramanian</last_name>
    <phone>+1 858-246-1277</phone>
    <email>viva-mind@health.ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerstin Kuehn-Wache</last_name>
    <phone>+49 345 5559900</phone>
    <email>clinics@vivoryon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Alzheimer's Disease Research Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PCND Neurology</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>USF Health Byrd Alzheimer's Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Carver College of Medicine</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Kentucky Sanders-Brown Center on Aging</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern Light Acadia Hospital</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health Tisch Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Abington Neurological Associates</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>October 28, 2022</last_update_submitted>
  <last_update_submitted_qc>October 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Mild Alzheimer's Disease</keyword>
  <keyword>Early Alzheimer's disease</keyword>
  <keyword>MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

